0 Replies
Related Articles
RNAi-based nanomedicines for targeted personalized therapy.
Adv Drug Deliv Rev. 2012 Sep 5;
Authors: Daka A, Peer D
Abstract
RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe,... Contine Reading & Discuss→
0 Replies
Related Articles
Virus-modified exosomes for targeted rna delivery; A new approach in nanomedicine.
Adv Drug Deliv Rev. 2012 Jul 19;
Authors: Koppers-Lalic D, Hogenboom MM, Middeldorp JM, Pegtel DM
Abstract
A major goal in biomedical research is to clinically reverse the cause of disease rather than treating the symptoms. Gene... Contine Reading & Discuss→
0 Replies
Related Articles
Polyplex-based Delivery of RNAi Therapeutics: Adverse Effects and Solutions.
Adv Drug Deliv Rev. 2012 Jul 13;
Authors: Ballarín-González B, Howard KA
Abstract
Small interfering RNA (siRNA) that silence genes by the process of RNA interference offers a new therapeutic modality for disease treatment. Polycation-based nanoparticles termed polyplexes have... Contine Reading & Discuss→
0 Replies
Related Articles
Toxicity Profile of RNAi Nanomedicines.
Adv Drug Deliv Rev. 2012 Jun 22;
Authors: Barros SA, Gollob JA
Abstract
The emerging class of RNA interference (RNAi) therapeutics is a fundamentally novel approach to treating human disease by enabling the pursuit of molecular targets considered "undruggable" by small molecules and... Contine Reading & Discuss→
